dalbavancin

11/19/2023 - "Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. "
09/01/2021 - "Dalbavancin was curative in all but one patient, whose signs and symptoms of infection improved. "
07/01/2020 - "According to this model, dalbavancin seems to have good efficacy for treating serious Gram-positive bone infections, including those caused by MRSA."
07/01/2015 - "Given dalbavancin exposures documented in children 12-17 years of age, and recognized dose proportionality, appropriate dosing can be modeled for pediatric phase 3 trials in acute bacterial skin and skin structure infections, to achieve the same exposure that is reported to be safe and effective in adults."
12/01/2022 - "Dalbavancin seems to be effective and safe as second-line treatment in severe Gram-positive infections. "

02/01/2016 - "Dalbavancin is effective in the treatment of MRSA rat sternal osteomyelitis."
02/01/2022 - "Dalbavancin administered as a 2-dose regimen is a safe and effective option for the treatment of osteomyelitis."
04/01/2020 - "Dalbavancin appears to be safe and effective for the management of osteomyelitis in adults. "
03/01/2019 - "Dalbavancin appears to be safe and effective in the treatment of osteomyelitis. "
07/01/2020 - "The aim of this study was to evaluate the efficacy of dalbavancin (dosed for either 7 or 14 days) in an MRSA-osteomyelitis tibial bone model. "

07/01/2022 - "Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections."
05/01/2022 - "Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020)."
01/01/2023 - "Dalbavancin in catheter-related bloodstream infections: a pilot study."
04/01/2022 - "However, as enterococci also commonly cause catheter-related bloodstream infections (C-RBSI), we assessed the bioactivity of frozen dalbavancin (D) and DH against enterococci. "
09/01/2015 - "Limited phase 2 data suggest dalbavancin also possesses activity in catheter-related bloodstream infections. "

05/01/2007 - "Phase III clinical trials comprising more than 1,500 patients evaluated once-weekly dalbavancin in Gram-positive skin and soft tissue infections (SSTIs). "
01/01/2023 - "Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs). "
01/01/2022 - "Dalbavancin is approved for the treatment of complicated skin and soft tissue infections. "
09/01/2021 - "Dalbavancin was approved in Europe in 2015 for skin and soft tissue infections.Hypothesis"
09/01/2020 - "Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections."

04/01/2023 - "However, only a few studies have been reported in the literature, and the use of dalbavancin remains limited. This article is a review of the currently available literature using dalbavancin for the treatment of infective endocarditis due to Gram-positive organisms. "
11/04/2023 - "Due to its long half-life, dalbavancin offers benefits for long-duration treatments, especially osteoarticular and infective endocarditis (IE). "
11/04/2023 - "Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis."
01/01/2023 - "We here report a case of successful treatment with dalbavancin of an infectious endocarditis caused by E. "
01/01/2023 - "A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis."